2015 will be more CONCRETE than 2014 was for AMBS:
Post# of 30025
1) LymPro will be generating sales & revenue and will be "monetized,"
2) Diagnostic Division will be spun off into separate entity,
3) AMBS will trade on the NASDAQ with institutional investors,
4) Eltoprazine LID Phase 2b trial will begin Q1,
5) ESS trial will begin Q2,
6) MANF/Retintis trial will begin 2H 2015
These are all solid reasons why the pps will go up substantially!